Alicia M. Michaud

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

O. Christophe, G. Ronzitti, Laetitia van Wittenberghe, 2018, Nature Communications.

Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy

Fen Fu, D. Ovchinnikov, G. Kovalev, 2018, PloS one.

ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia

R. Chandler, C. Venditti, I. Manoli, 2021, Molecular therapy. Methods & clinical development.

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles

T. Kishimoto, P. Ilyinskii, C. Roy, 2021, Science Advances.

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

O. Christophe, G. Ronzitti, Laetitia van Wittenberghe, 2018, Nature Communications.

Synergistic activity of IL-2 mutein with tolerogenic ImmTOR nanoparticles leads to massive expansion of antigen-specific Tregs and protection against autoimmune disease

Jamie B. Spangler, P. Traber, Ning Li, 2023, bioRxiv.

Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.

P. Ilyinskii, C. Roy, D. VanDyke, 2023, Journal of autoimmunity.

Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents

P. Ilyinskii, C. Roy, S. Leung, 2023, PNAS nexus.